Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Impressive results from MDT-BRIDGE at ESMO25 from Dr. Martin Reck.
Patients with resectable or borderline had 2 cycles of durvalumab + chemo then reassessed at MDT. If resectable at start, 95% remained resectable. If borderline, 82% were then felt to be resectable.”
Eric K. Singhi, Thoracic Medical Oncologist and Assistant Professor at MD Anderson Cancer Center, shared this post, adding:
“Can we turn “borderline resectable” lung cancer into resectable? In the MDTBRIDGE trial, after just 2 cycles of durvalumab + chemo, 82% of borderline-resectable NSCLC cases became resectable at MDC reassessment.”
You Can Also Read:
ESMO Announces the 2025 Society Award Winners
ESMO 2025 Day 1 Highlights Not to Miss
